About: http://data.cimple.eu/news-article/13a69487247b573e04ee360e880f93678c5e21672e3b81bf4cfba3d0     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : schema:NewsArticle, within Data Space : data.cimple.eu associated with source document(s)

AttributesValues
rdf:type
schema:articleBody
  • Pharma giants Sanofi and GSK are to receive up to $2.1 billion from the US government for the development of a COVID-19 vaccine, the companies said Friday, as the world continues to be ravaged by the coronavirus epidemic. The United States had identified a vaccine candidate under investigation by Sanofi and GSK for its "Operation Warp Speed," which aims to speedily secure millions of doses of a safe and effective COVID-19 vaccine. The vaccine will combine a Sanofi-developed antigen, which stimulates the production of germ-killing antibodies, with GSK's adjuvant technology, a substance that bolsters the immune response triggered by a vaccine, they said in a statement. The American money, it added, will "help fund the development activities and secure scale-up of Sanofi's and GSK's manufacturing capabilities in the United States for the recombinant protein-based, adjuvanted vaccine, resulting in a significant increase in capacity." In April, Sanofi and GSK announced they were joining forces on a COVID-19 vaccine they hoped to have in clinical trials this year, potentially making it available in the second half of 2021. On Friday, they said there were also discussions with the European Commission and other governments "to ensure global access to a novel coronavirus vaccine." Alex Azar of the US Department of Health and Human Services (HHS) said the portfolio of vaccines being assembled under Operation Warp Speed "increases the odds that we will have at least one safe, effective vaccine as soon as the end of this year." "Today's investment supports the Sanofi and GSK adjuvanted product all the way through clinical trials and manufacturing, with the potential to bring hundreds of millions of safe and effective doses to the American people," the statement quoted him as saying. "The global need for a vaccine to help prevent COVID-19 is massive, and no single vaccine or company will be able to meet the global demand alone," added Thomas Triomphe, the head of Sanofi Pasteur, the company's vaccine division. mlr/js/cdw
schema:headline
  • US promises $2.1 bn for Sanofi, GSK coronavirus vaccine
schema:mentions
schema:author
schema:datePublished
http://data.cimple...sPoliticalLeaning
http://data.cimple...logy#hasSentiment
http://data.cimple...readability_score
http://data.cimple...tology#hasEmotion
Faceted Search & Find service v1.16.115 as of Oct 09 2023


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 07.20.3238 as of Jul 16 2024, on Linux (x86_64-pc-linux-musl), Single-Server Edition (126 GB total memory, 11 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software